Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer.

Couture F, Sabbagh R, Kwiatkowska A, Desjardins R, Guay SP, Bouchard L, Day R.

Cancer Res. 2017 Dec 15;77(24):6863-6879. doi: 10.1158/0008-5472.CAN-17-1397. Epub 2017 Oct 9.

PMID:
28993410
2.

Thrombin activation of protein C requires prior processing by a liver proprotein convertase.

Essalmani R, Susan-Resiga D, Guillemot J, Kim W, Sachan V, Awan Z, Chamberland A, Asselin MC, Ly K, Desjardins R, Day R, Prat A, Seidah NG.

J Biol Chem. 2017 Aug 18;292(33):13565. doi: 10.1074/jbc.A116.77040. No abstract available.

3.

Rational Design of a Highly Potent and Selective Peptide Inhibitor of PACE4 by Salt Bridge Interaction with D160 at Position P3.

Dianati V, Shamloo A, Kwiatkowska A, Desjardins R, Soldera A, Day R, Dory YL.

ChemMedChem. 2017 Aug 8;12(15):1169-1172. doi: 10.1002/cmdc.201700300. Epub 2017 Jul 19.

PMID:
28722823
4.

Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations.

Łepek T, Kwiatkowska A, Couture F, Ly K, Desjardins R, Dory Y, Prahl A, Day R.

Eur J Cell Biol. 2017 Aug;96(5):476-485. doi: 10.1016/j.ejcb.2017.04.001. Epub 2017 Apr 23.

PMID:
28483279
5.

Thrombin activation of protein C requires prior processing by a liver proprotein convertase.

Essalmani R, Susan-Resiga D, Guillemot J, Kim W, Sachan V, Awan Z, Chamberland A, Asselin MC, Ly K, Desjardins R, Day R, Prat A, Seidah NG.

J Biol Chem. 2017 Jun 23;292(25):10564-10573. doi: 10.1074/jbc.M116.770040. Epub 2017 May 3. Erratum in: J Biol Chem. 2017 Aug 18;292(33):13565.

PMID:
28468828
6.

Potential methane emission reductions for two manure treatment technologies.

VanderZaag AC, Baldé H, Crolla A, Gordon RJ, Ngwabie NM, Wagner-Riddle C, Desjardins R, MacDonald JD.

Environ Technol. 2018 Apr;39(7):851-858. doi: 10.1080/09593330.2017.1313317. Epub 2017 Apr 26.

PMID:
28355494
7.

PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression.

Panet F, Couture F, Kwiatkowska A, Desjardins R, Guérin B, Day R.

Eur J Cell Biol. 2017 Aug;96(5):469-475. doi: 10.1016/j.ejcb.2017.03.006. Epub 2017 Mar 21.

PMID:
28347547
8.

Positional Scanning Identifies the Molecular Determinants of a High Affinity Multi-Leucine Inhibitor for Furin and PACE4.

Małuch I, Levesque C, Kwiatkowska A, Couture F, Ly K, Desjardins R, Neugebauer WA, Prahl A, Day R.

J Med Chem. 2017 Apr 13;60(7):2732-2744. doi: 10.1021/acs.jmedchem.6b01499. Epub 2017 Mar 24.

PMID:
28287731
9.

Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.

Coriat R, Faivre SJ, Mir O, Dreyer C, Ropert S, Bouattour M, Desjardins R, Goldwasser F, Raymond E.

Int J Nanomedicine. 2016 Nov 21;11:6207-6216. eCollection 2016.

10.

Does Fall Removal of the Dairy Manure Sludge in a Storage Tank Reduce Subsequent Methane Emissions?

Baldé H, VanderZaag AC, Burtt SD, Gordon RJ, Desjardins RL.

J Environ Qual. 2016 Nov;45(6):2038-2043. doi: 10.2134/jeq2016.03.0083.

PMID:
27898776
12.

Methane emissions from digestate at an agricultural biogas plant.

Baldé H, VanderZaag AC, Burtt SD, Wagner-Riddle C, Crolla A, Desjardins RL, MacDonald DJ.

Bioresour Technol. 2016 Sep;216:914-22. doi: 10.1016/j.biortech.2016.06.031. Epub 2016 Jun 11.

PMID:
27323243
13.

The proprotein convertase PC1/3 regulates TLR9 trafficking and the associated signaling pathways.

Duhamel M, Rodet F, Murgoci AN, Desjardins R, Gagnon H, Wisztorski M, Fournier I, Day R, Salzet M.

Sci Rep. 2016 Jan 18;6:19360. doi: 10.1038/srep19360.

14.

Novel Insights into Structure-Activity Relationships of N-Terminally Modified PACE4 Inhibitors.

Kwiatkowska A, Couture F, Levesque C, Ly K, Beauchemin S, Desjardins R, Neugebauer W, Dory YL, Day R.

ChemMedChem. 2016 Feb 4;11(3):289-301. doi: 10.1002/cmdc.201500532. Epub 2016 Jan 11.

PMID:
26751825
15.

Attitudes Toward Chiropractic: A Survey of Canadian Obstetricians.

Weis CA, Stuber K, Barrett J, Greco A, Kipershlak A, Glenn T, Desjardins R, Nash J, Busse J.

J Evid Based Complementary Altern Med. 2016 Apr;21(2):92-104. doi: 10.1177/2156587215604073. Epub 2015 Sep 8.

PMID:
26350243
16.

Molecular Consequences of Proprotein Convertase 1/3 (PC1/3) Inhibition in Macrophages for Application to Cancer Immunotherapy: A Proteomic Study.

Duhamel M, Rodet F, Delhem N, Vanden Abeele F, Kobeissy F, Nataf S, Pays L, Desjardins R, Gagnon H, Wisztorski M, Fournier I, Day R, Salzet M.

Mol Cell Proteomics. 2015 Nov;14(11):2857-77. doi: 10.1074/mcp.M115.052480. Epub 2015 Sep 1.

17.

Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity.

Couture F, Ly K, Levesque C, Kwiatkowska A, Ait-Mohand S, Desjardins R, Guérin B, Day R.

Biomed Res Int. 2015;2015:824014. doi: 10.1155/2015/824014. Epub 2015 May 31.

18.

PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation.

Levesque C, Couture F, Kwiatkowska A, Desjardins R, Guérin B, Neugebauer WA, Day R.

Oncotarget. 2015 Feb 28;6(6):3680-93.

19.

Chymase inhibitor-sensitive synthesis of endothelin-1 (1-31) by recombinant mouse mast cell protease 4 and human chymase.

Semaan W, Desbiens L, Houde M, Labonté J, Gagnon H, Yamamoto D, Takai S, Laidlaw T, Bkaily G, Schwertani A, Pejler G, Levesque C, Desjardins R, Day R, D'Orléans-Juste P.

Biochem Pharmacol. 2015 Mar 15;94(2):91-100. doi: 10.1016/j.bcp.2015.02.001. Epub 2015 Feb 7.

PMID:
25667044
20.

Impact of management strategies on the global warming potential at the cropping system level.

Goglio P, Grant BB, Smith WN, Desjardins RL, Worth DE, Zentner R, Malhi SS.

Sci Total Environ. 2014 Aug 15;490:921-33. doi: 10.1016/j.scitotenv.2014.05.070. Epub 2014 Jun 6.

PMID:
24911772
21.

Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target.

Longuespée R, Couture F, Levesque C, Kwiatkowska A, Desjardins R, Gagnon S, Vergara D, Maffia M, Fournier I, Salzet M, Day R.

Transl Oncol. 2014 May 9. pii: S1936-5233(14)00043-6. doi: 10.1016/j.tranon.2014.04.008. [Epub ahead of print]

22.

Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.

Ly K, Saavedra YG, Canuel M, Routhier S, Desjardins R, Hamelin J, Mayne J, Lazure C, Seidah NG, Day R.

J Biol Chem. 2014 Jun 20;289(25):17732-46. doi: 10.1074/jbc.M113.541094. Epub 2014 May 7.

23.

Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin.

Gagnon H, Beauchemin S, Kwiatkowska A, Couture F, D'Anjou F, Levesque C, Dufour F, Desbiens AR, Vaillancourt R, Bernard S, Desjardins R, Malouin F, Dory YL, Day R.

J Med Chem. 2014 Jan 9;57(1):29-41. doi: 10.1021/jm400633d. Epub 2013 Dec 23.

PMID:
24359257
24.

Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor.

Kwiatkowska A, Couture F, Levesque C, Ly K, Desjardins R, Beauchemin S, Prahl A, Lammek B, Neugebauer W, Dory YL, Day R.

J Med Chem. 2014 Jan 9;57(1):98-109. doi: 10.1021/jm401457n. Epub 2013 Dec 18.

PMID:
24350995
25.

Knockdown strategies for the study of proprotein convertases and proliferation in prostate cancer cells.

D'Anjou F, Couture F, Desjardins R, Day R.

Methods Mol Biol. 2014;1103:67-82. doi: 10.1007/978-1-62703-730-3_6.

PMID:
24318887
26.

Disruption of the expression of the proprotein convertase PC7 reduces BDNF production and affects learning and memory in mice.

Wetsel WC, Rodriguiz RM, Guillemot J, Rousselet E, Essalmani R, Kim IH, Bryant JC, Marcinkiewicz J, Desjardins R, Day R, Constam DB, Prat A, Seidah NG.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17362-7. doi: 10.1073/pnas.1314698110. Epub 2013 Oct 7.

27.

Carbon footprint of Canadian dairy products: calculations and issues.

Vergé XP, Maxime D, Dyer JA, Desjardins RL, Arcand Y, Vanderzaag A.

J Dairy Sci. 2013 Sep;96(9):6091-104. doi: 10.3168/jds.2013-6563. Epub 2013 Jul 5.

28.

Proprotein convertase 1/3 (PC1/3) in the rat alveolar macrophage cell line NR8383: localization, trafficking and effects on cytokine secretion.

Gagnon H, Refaie S, Gagnon S, Desjardins R, Salzet M, Day R.

PLoS One. 2013 Apr 24;8(4):e61557. doi: 10.1371/journal.pone.0061557. Print 2013.

29.

Role of proprotein convertases in prostate cancer progression.

Couture F, D'Anjou F, Desjardins R, Boudreau F, Day R.

Neoplasia. 2012 Nov;14(11):1032-42.

30.

The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells.

Levesque C, Fugère M, Kwiatkowska A, Couture F, Desjardins R, Routhier S, Moussette P, Prahl A, Lammek B, Appel JR, Houghten RA, D'Anjou F, Dory YL, Neugebauer W, Day R.

J Med Chem. 2012 Dec 13;55(23):10501-11. doi: 10.1021/jm3011178. Epub 2012 Nov 14.

31.

Disruption of proprotein convertase 1/3 (PC1/3) expression in mice causes innate immune defects and uncontrolled cytokine secretion.

Refaie S, Gagnon S, Gagnon H, Desjardins R, D'Anjou F, D'Orléans-Juste P, Zhu X, Steiner DF, Seidah NG, Lazure C, Salzet M, Day R.

J Biol Chem. 2012 Apr 27;287(18):14703-17. doi: 10.1074/jbc.M111.323220. Epub 2012 Mar 6.

32.

A Greenhouse Gas and Soil Carbon Model for Estimating the Carbon Footprint of Livestock Production in Canada.

Vergé XP, Dyer JA, Worth DE, Smith WN, Desjardins RL, McConkey BG.

Animals (Basel). 2012 Sep 4;2(3):437-54. doi: 10.3390/ani2030437.

33.

Methane emissions from a dairy feedlot during the fall and winter seasons in Northern China.

Gao Z, Yuan H, Ma W, Liu X, Desjardins RL.

Environ Pollut. 2011 May;159(5):1183-9. doi: 10.1016/j.envpol.2011.02.003. Epub 2011 Feb 26.

PMID:
21354680
34.

Presence of task-1 channel in the laryngeal mucosa in the newborn lamb.

Bournival V, Desjardins R, Campbell S, Roberge C, Doueik A, Gendron L, Payet MD, Gallo-Payet N, Day R, Praud JP.

Exp Lung Res. 2011 May;37(4):205-11. doi: 10.3109/01902148.2010.536610. Epub 2011 Feb 11.

PMID:
21309733
35.

Lifelong educational practices and resources in enabling health literacy among older adults.

Wister AV, Malloy-Weir LJ, Rootman I, Desjardins R.

J Aging Health. 2010 Sep;22(6):827-54. doi: 10.1177/0898264310373502. Epub 2010 Jul 1.

PMID:
20595098
36.

Selective and potent furin inhibitors protect cells from anthrax without significant toxicity.

Remacle AG, Gawlik K, Golubkov VS, Cadwell GW, Liddington RC, Cieplak P, Millis SZ, Desjardins R, Routhier S, Yuan XW, Neugebauer WA, Day R, Strongin AY.

Int J Biochem Cell Biol. 2010 Jun;42(6):987-95. doi: 10.1016/j.biocel.2010.02.013. Epub 2010 Mar 1.

37.

Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route.

Poirier S, Mayer G, Poupon V, McPherson PS, Desjardins R, Ly K, Asselin MC, Day R, Duclos FJ, Witmer M, Parker R, Prat A, Seidah NG.

J Biol Chem. 2009 Oct 16;284(42):28856-64. doi: 10.1074/jbc.M109.037085. Epub 2009 Jul 27.

38.

Autocatalytic activation of the furin zymogen requires removal of the emerging enzyme's N-terminus from the active site.

Gawlik K, Shiryaev SA, Zhu W, Motamedchaboki K, Desjardins R, Day R, Remacle AG, Stec B, Strongin AY.

PLoS One. 2009;4(4):e5031. doi: 10.1371/journal.pone.0005031. Epub 2009 Apr 7.

39.

Estimating gas emissions from multiple sources using a backward Lagrangian stochastic model.

Gao Z, Desjardins RL, van Haarlem RP, Flesch TK.

J Air Waste Manag Assoc. 2008 Nov;58(11):1415-21.

PMID:
19044157
40.

Including operational data in QMRA model: development and impact of model inputs.

Jaidi K, Barbeau B, Carrière A, Desjardins R, Prévost M.

J Water Health. 2009 Mar;7(1):77-95. doi: 10.2166/wh.2009.133.

PMID:
18957777
41.

Substrate cleavage analysis of furin and related proprotein convertases. A comparative study.

Remacle AG, Shiryaev SA, Oh ES, Cieplak P, Srinivasan A, Wei G, Liddington RC, Ratnikov BI, Parent A, Desjardins R, Day R, Smith JW, Lebl M, Strongin AY.

J Biol Chem. 2008 Jul 25;283(30):20897-906. doi: 10.1074/jbc.M803762200. Epub 2008 May 27.

42.

Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens.

Shiryaev SA, Remacle AG, Ratnikov BI, Nelson NA, Savinov AY, Wei G, Bottini M, Rega MF, Parent A, Desjardins R, Fugere M, Day R, Sabet M, Pellecchia M, Liddington RC, Smith JW, Mustelin T, Guiney DG, Lebl M, Strongin AY.

J Biol Chem. 2007 Jul 20;282(29):20847-53. Epub 2007 May 30.

43.

Strain-specific steroidal control of pituitary function.

Lee SN, Peng B, Desjardins R, Pintar JE, Day R, Lindberg I.

J Endocrinol. 2007 Mar;192(3):515-25.

44.

Targeted ablation of the chromogranin a (Chga) gene: normal neuroendocrine dense-core secretory granules and increased expression of other granins.

Hendy GN, Li T, Girard M, Feldstein RC, Mulay S, Desjardins R, Day R, Karaplis AC, Tremblay ML, Canaff L.

Mol Endocrinol. 2006 Aug;20(8):1935-47. Epub 2006 Mar 23.

PMID:
16556729
45.

Impacts of water quality on chlorine and chlorine dioxide efficacy in natural waters.

Barbeau B, Desjardins R, Mysore C, Prévost M.

Water Res. 2005 May;39(10):2024-33.

PMID:
15922397
46.

Is the integration of heard and seen speech mandatory for infants?

Desjardins RN, Werker JF.

Dev Psychobiol. 2004 Dec;45(4):187-203.

PMID:
15549681
47.

Can peripheral venous pressure be interchangeable with central venous pressure in patients undergoing cardiac surgery?

Desjardins R, Denault AY, Bélisle S, Carrier M, Babin D, Lévesque S, Martineau R.

Intensive Care Med. 2004 Apr;30(4):627-32. Epub 2003 Nov 5.

PMID:
14600810
48.

Biosynthesis of proopiomelanocortin-derived peptides in prohormone convertase 2 and 7B2 null mice.

Laurent V, Jaubert-Miazza L, Desjardins R, Day R, Lindberg I.

Endocrinology. 2004 Feb;145(2):519-28. Epub 2003 Oct 23.

PMID:
14576186
49.

[Debates on religion among Montreal physicians].

Desjardins R.

Can Bull Med Hist. 2001;18(2):325-47. French.

PMID:
14518462
50.

Retrospective cohort study of the clinical performance of 1-stage dental implants.

Carr AB, Choi YG, Eckert SE, Desjardins RP.

Int J Oral Maxillofac Implants. 2003 May-Jun;18(3):399-405.

PMID:
12814315

Supplemental Content

Loading ...
Support Center